Greenland Mines Ltd. (GRML)
GRML trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$5.54
-7.97% on the day
Market cap
$73.9M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | GRML on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001907223 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-09-28 |
| Latest annual report AMENDMENT NO. 1 TO FORM 10-K | 10-K/A | 2026-08-14 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-08-17 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-02 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-06-22 |
Source: SEC EDGAR submissions feed, 266 recent filings. All filings on EDGAR.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| GRMLW | Greenland Mines Ltd Warrant | $0.6101 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OKYO | OKYO Pharma Limited | $1.44 | -0.17% | $75.4M |
| CGTX | Cognition Therapeutics Inc. | $0.8017 | -6.44% | $76.2M |
| PTHS | Pelthos Therapeutics Inc. | $20.29 | +3.94% | $77.7M |
| CRDF | Cardiff Oncology Inc. | $1.01 | -2.88% | $78.6M |
| NMRA | Neumora Therapeutics Inc. | $0.3702 | -15.34% | $69.6M |
| CSBR | Champions Oncology Inc. | $4.90 | -1.08% | $68.2M |
| LONA | LeonaBio Inc. | $6.43 | +4.30% | $60.6M |
| ATRA | Atara Biotherapeutics Inc. | $9.30 | -0.80% | $93.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier